Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al

Clin Oncol (R Coll Radiol). 2016 Oct;28(10):666-7. doi: 10.1016/j.clon.2016.07.004. Epub 2016 Jul 29.

Authors

N D James¹, M R Sydes², N W Clarke³, A W S Ritchie², M K B Parmar²

Affiliations

¹ Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK.
² MRC Clinical Trials Unit at UCL, London, UK.
³ Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.

PMID: 27477123
DOI: 10.1016/j.clon.2016.07.004

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Docetaxel
Humans
Male
Neutropenia
Prostatic Neoplasms*
Taxoids*

Substances

Taxoids
Docetaxel